A Study in Schizophrenic Patients

Phase 2 Terminated 82 enrolled Denovo Biopharma LLC

RandomizedParallel-groupTriple-blindTreatment

Summary

This study is designed to compare 3 doses of LY2140023 for the treatment of schizophrenia as assessed at endpoint (up to 7 weeks) using the Clinical Utility Index (CUI), a measure of efficacy, safety, and tolerability.

Timeline

Start: 2010-05
Primary completion: 2012-09
Completion: 2012-09

Outcome

Outcome not reported

Stopped: “The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population.”

Publications

Kinon BJ, Millen BA, Zhang L, McKinzie DL. Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia. Biol Psychiatry. 2015 Dec 1;78(11):754-62. doi: 10.1016/j.biopsych.2015.03.016. Epub 2015 Mar 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LY2140023	Unknown	10 mg	Oral
Subject	LY2140023	Unknown	80 mg	Oral
Subject	LY2140023	Unknown	160 mg	Oral